NasdaqGM:CLSD

Stock Analysis Report

Executive Summary

Clearside Biomedical, Inc., a late-stage clinical biopharmaceutical company, develops pharmacological therapies to restore and preserve vision for people with serious eye diseases.

Snowflake

Fundamentals

Mediocre balance sheet with limited growth.

Share Price & News

How has Clearside Biomedical's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

1.5%

CLSD

-0.1%

US Pharmaceuticals

1.0%

US Market


1 Year Return

-86.4%

CLSD

-6.2%

US Pharmaceuticals

6.7%

US Market

Return vs Industry: CLSD underperformed the US Pharmaceuticals industry which returned -6.2% over the past year.

Return vs Market: CLSD underperformed the US Market which returned 6.7% over the past year.


Share holder returns

CLSDIndustryMarket
7 Day1.5%-0.1%1.0%
30 Day-2.5%-0.5%-1.8%
90 Day-35.3%-2.6%-1.8%
1 Year-86.4%-86.4%-3.9%-6.2%9.1%6.7%
3 Year-96.4%-96.4%17.4%9.1%46.1%36.6%
5 Yearn/a28.0%14.5%66.9%48.6%

Price Volatility Vs. Market

How volatile is Clearside Biomedical's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Clearside Biomedical undervalued based on future cash flows and its price relative to the stock market?

2.25x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Undervalued: Insufficient data to calculate CLSD's fair value to establish if it is undervalued.

Significantly Undervalued: Insufficient data to calculate CLSD's fair value to establish if it is undervalued.


Price Based on Earnings

PE vs Industry: CLSD is unprofitable, so we can't compare its PE Ratio to the Pharmaceuticals industry average.

PE vs Market: CLSD is unprofitable, so we can't compare its PE Ratio to the US market.


Price Based on Expected Growth

Low PEG Ratio: Insufficient data to calculate CLSD's PEG Ratio to determine if it is good value.


Price Based on Value of Assets

PB vs Industry: CLSD is good value based on its PB Ratio (2.3x) compared to the US Pharmaceuticals industry average (2.8x).


Next Steps

Future Growth

How is Clearside Biomedical expected to perform in the next 1 to 3 years based on estimates from 7 analysts?

52.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Earnings vs Savings Rate: CLSD is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: CLSD is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: CLSD is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: CLSD's revenue (67.4% per year) is forecast to grow faster than the US market (7.3% per year).

High Growth Revenue: CLSD's revenue (67.4% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Estimates


Future Return on Equity

High Future ROE: Insufficient data to determine if CLSD's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Clearside Biomedical performed over the past 5 years?

-43.3%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: CLSD is unprofitable, and losses have increased over the past 5 years at a rate of -43.3% per year.

Accelerating Growth: Unable to compare CLSD's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CLSD is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (24.3%).


Return on Equity

High ROE: CLSD has a negative Return on Equity (-516.61%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: CLSD is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: CLSD is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Clearside Biomedical's financial position?


Financial Position Analysis

Short Term Liabilities: CLSD's short term assets ($27.9M) exceeds its short term liabilities ($8.0M)

Long Term Liabilities: CLSD's short term assets ($27.9M) exceeds its long term liabilities ($8.9M)


Debt to Equity History and Analysis

Debt Level: CLSD's debt to equity ratio (78.3%) is considered high

Reducing Debt: CLSD had negative shareholder equity 5 years ago, but is now positive and has therefore improved.


Balance Sheet

Inventory Level: CLSD has a low level of unsold assets or inventory.

Debt Coverage by Assets: CLSD's debt is covered by short term assets (assets are 2.761950x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: CLSD has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: CLSD has less than a year of cash runway if free cash flow continues to reduce at historical rates of -45.2% each year


Next Steps

Dividend

What is Clearside Biomedical's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.5%markettop25%3.8%industryaverage2.3%forecastin3Yearsn/a

Current dividend yield vs market & industry


Dividend Yield and Payments Analysis

Notable Dividend: Unable to evaluate CLSD's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate CLSD's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if CLSD's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CLSD's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CLSD's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of Clearside Biomedical's salary, the management and board of directors tenure and is there insider trading?

1.4yrs

Average management tenure


CEO

George Lasezkay (67yo)

0.5yrs

Tenure

US$150,157

Compensation

Dr. George M. Lasezkay, Pharm.D, & J.D. has been Interim Chief Executive Officer at Clearside BioMedical, Inc. since April 8, 2019. He serves as Principal of Turning Point Consultants LLC. Dr. Lasezkay has ...


Management Age and Tenure

1.4yrs

Average Tenure

52yo

Average Age

Experienced Management: CLSD's management team is not considered experienced ( 1.4 years average tenure), which suggests a new team.


Board Age and Tenure

2.9yrs

Average Tenure

61yo

Average Age

Experienced Board: CLSD's board of directors are not considered experienced ( 2.9 years average tenure), which suggests a new board.


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

BuyUS$13,60018 Mar 19
Charles Deignan
EntityIndividual
Role
Chief Financial Officer
Chief Financial Officer
Shares10,000
Max PriceUS$1.36
BuyUS$10,88006 Dec 18
Clay Thorp
EntityIndividual
Role
Member of the Board of Directors
Director
Shares8,000
Max PriceUS$1.36

Ownership Breakdown


Management Team

  • George Lasezkay (67yo)

    Interim CEO & Director

    • Tenure: 0.5yrs
    • Compensation: US$150.16k
  • Jenny Kobin (52yo)

    Head of Investor Relations

    • Tenure: 0yrs
  • Leslie Zacks (50yo)

    General Counsel

    • Tenure: 1.1yrs
  • Charlie Deignan (55yo)

    Chief Financial Officer

    • Tenure: 7.8yrs
    • Compensation: US$434.36k
  • Thomas Ciulla

    Chief Medical Officer

    • Tenure: 1yrs
  • Rick McElheny

    Vice President of Corporate Development

    • Tenure: 1.8yrs
  • Brion Raymond (49yo)

    Chief Commercial Officer

    • Tenure: 1.7yrs
    • Compensation: US$954.31k

Board Members

  • Christy Shaffer (61yo)

    Director

    • Tenure: 7.8yrs
    • Compensation: US$140.16k
  • George Lasezkay (67yo)

    Interim CEO & Director

    • Tenure: 0.5yrs
    • Compensation: US$150.16k
  • Jeff Edwards (58yo)

    Director

    • Tenure: 1.1yrs
    • Compensation: US$119.42k
  • Clay Thorp (51yo)

    Director

    • Tenure: 7.8yrs
    • Compensation: US$148.32k
  • Bill Humphries (53yo)

    Chairman of the Board

    • Tenure: 1.7yrs
    • Compensation: US$176.99k
  • Harold Shlevin (69yo)

    Member of the Scientific Advisory Board

    • Tenure: 0yrs
  • Mark Prausnitz

    Chairman of the Scientific Advisory Board

    • Tenure: 0yrs
  • Rick Croarkin (65yo)

    Director

    • Tenure: 3.7yrs
    • Compensation: US$158.16k
  • Hank Edelhauser

    Member of the Scientific Advisory Board

    • Tenure: 0yrs

Company Information

Clearside Biomedical, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Clearside Biomedical, Inc.
  • Ticker: CLSD
  • Exchange: NasdaqGM
  • Founded: 2011
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$29.075m
  • Shares outstanding: 37.76m
  • Website: https://www.clearsidebio.com

Number of Employees


Location

  • Clearside Biomedical, Inc.
  • 900 North Point Parkway
  • Suite 200
  • Alpharetta
  • Georgia
  • 30005
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CLSDNasdaqGM (Nasdaq Global Market)YesCommon StockUSUSDJun 2016
CLMBST (Boerse-Stuttgart)YesCommon StockDEEURJun 2016

Biography

Clearside Biomedical, Inc., a late-stage clinical biopharmaceutical company, develops pharmacological therapies to restore and preserve vision for people with serious eye diseases. It develops XIPERE, a tr ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/14 03:15
End of Day Share Price2019/10/11 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

© 2018 SIMPLY WALL STREET PTY LTD, COMMUNITY DESIGN 2845206, US DESIGN PATENT #29/544/281, EUROPEAN DESIGN REGISTRATION #2845206, STANDARD & POOR’S FINANCIAL SERVICES LLC. ALL RIGHTS RESERVED.

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.

Copyright © 2018, Standard & Poor’s Financial Services LLC. Reproduction of S&P Capital IQ in any form is prohibited except with the prior written permission of S&P. S&P does not guarantee the accuracy, adequacy, completeness or availability of any information and is not responsible for any errors or omissions, regardless of the cause or for the results obtained from the use of such information. S&P DISCLAIMS ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE. In no event shall S&P be liable for any direct, indirect, special or consequential damages, costs, expenses, legal fees, or losses (including lost income or lost profit and opportunity costs) in connection with subscriber’s or others’ use of S&P Capital IQ. (2018)